Praziquantel efficacy

Efficacy of single vs. multiple Praziquantel MDA against Schistosoma mansoni infections among primary school children

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201601001416338

Enrollment

513

Registered

2016-01-09

Start date

2015-09-28

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin and Connective Tissue Diseases Paediatrics

Interventions

Praziquantel

Praziquantel double treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: School children between 6 - 19 years of age Children agree to participate in the study Parents give a written informed consent

Exclusion criteria

Exclusion criteria: History of being clinically ill and used drug within a period of two weeks before the study Refusal of parents to sign a written informed consent Evidence of being sick during the time of recruitment

Design outcomes

Primary

Measure	Time frame
Egg reduction rate (ERR);Cure rate (CR)	—

Secondary

Measure	Time frame
Regression of morbidities	—

Countries

United Republic of Tanzania

Contacts

Public ContactJoram Buza

Supervisor

buza@nm-aist.ac.tz+255767012616

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026